Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourLeaning Bearish
15 minBearish
5 minLeaning Bullish
Daily trend turns down below $3.26
Key levels
Resistance$158.07
Support$12.15
Support$5.01
Latest news & SEC filings
No headlines in the last 90 days.
Greenwich LifeSciences develops an experimental breast cancer treatment called GLSI-100, which pairs the GP2 peptide with sargramostim to help the immune system target HER2-expressing tumors. The company is running a late-stage study of this therapy in patients who have finished standard HER2-directed treatment after surgery. It works with outside manufacturers and research organizations and enrolls participants at sites in the United States and Europe.
Based on the company's 10-K filed Jun 1, 2026.
Nasdaq · Healthcare
SEPT Low Target
$58.65
SEPT Mid Target
$69.00
SEPT High Target
$79.35
Analyst Consensus
$69.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GLSI.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$51.78
5
Moat Score
NONE
1/9
Piotroski Score
-9.0
Altman Z-Score
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
LOW
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-6.72%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for GLSI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:59:17 | $16.51 | 6,600 | $$109K | BUY |
| 19:58:34 | $16.30 | 6,600 | $$108K | SELL |
| 16:22:26 | $16.55 | 4,545 | $$75K | SELL |
| 16:07:54 | $16.67 | 2,782 | $$46K | SELL |
| 16:07:03 | $16.62 | 1,000 | $$17K | BUY |
5 dark pool trades shown · $$355K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Greenwich LifeSciences, Inc. (GLSI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Greenwich LifeSciences, Inc. (GLSI) is at $16.09, up 0.12% (+$0.02) at the Nov 11, 2026 close.
The average analyst price target for GLSI is $69.00, ranging from $69 to $69, based on 1 analysts. Latest: HC Wainwright & Co. maintains on Jul 21, 2026.
Analyst ratings for GLSI: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
GLSI last reported on Aug 11, 2026: EPS -$0.27 vs -$0.33 expected — a beat of 18.2%.
GLSI does not currently pay a dividend.
Support: $12.15, $5.01, $3.26. Resistance: $158.07.
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.